This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NPPB / Natriuretic peptides B · Western blot design guide
Design a Western Blot for NPPB
Real validated NPPB Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-NPPB WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
NPPB Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~14.7 kDa | |
| Gel | 15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Glycosylated + Cleaved | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated NPPB Western Blot Protocols
The M01186-2 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human plasma lysate (catalog M01186-2) |
| Gel % | 15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.2 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M01186-2; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected NPPB Western Blot Band Size?
The full-length NPPB precursor is predicted at 14.7 kDa; cleavage and O-linked modifications could affect migration, but no empirical band size is supplied.
| Band near 14.7 kDa | Consistent with the predicted full-length precursor, pending identity controls |
| Band below 14.7 kDa | Could reflect cleavage of the 1–26 signal peptide |
| Band above 14.7 kDa | Could reflect O-linked modification, including chondroitin sulfate at Ser41 |
| Little or no band in whole-cell lysate | NT-proBNP is secreted and detected in blood |
💡Expected NPPB appearanceUniProt predicts a 14.7 kDa full-length precursor; signal-peptide cleavage and O-linked modifications may alter migration, but no empirical band size is supplied, so confirm identity with controls.
| Predicted full-length mass | 14.7 kDa is the sequence-based precursor mass, not a validated blot position |
| Signal peptide at residues 1–26 | Cleavage can produce a smaller species than the full-length precursor |
| O-linked chondroitin sulfate at Ser41 | May increase apparent size when present; its migration effect is not established |
| O-linked HexNAc sites at Thr62 and Thr84 | Partially occupied sites may affect apparent migration when modified |
| O-linked HexNAc sites at Ser63, Ser70, Thr74, Ser79 and Thr97 | Modification may affect apparent migration; no shift is quantified |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | NT-proBNP is secreted | Check conditioned medium or plasma with a suitable positive control |
| Band higher than expected | O-linked modification is possible at annotated sites | Compare with a validated positive sample and assess glycosylation with an appropriate treatment |
| Band lower than expected | The 1–26 signal peptide may be cleaved | Check antibody epitope coverage and compare with a validated positive sample |
| Broad smear instead of sharp band | Variable O-linked modification is possible but unproven as the cause | Compare treated and untreated samples with a positive control |
| Multiple bands | Signal-peptide processing or O-linked modification could contribute | Use antibody and sample controls to establish which bands contain NPPB |
| Weak or no signal | A secreted target may be scarce in the tested cellular fraction | Test an appropriate extracellular sample and verify antibody performance with a positive control |
Experiment evidence
Western blot images showing NPPB band
M01186-2 · NPPB
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NPPB Western blot
🧪For positive controls for NPPB in Western blot, you can use no HPA-validated tissue or cell sample because none is supplied.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: NPPB is secreted and detected in blood, so whole-cell lysate may give a weak signal.
HPA tissue expression evidence for NPPB
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced NPPB Western Blot Tips
Deeper troubleshooting and optimisation questions for NPPB, answered from its protein features.
How should NPPB band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could annotated isoforms explain multiple NPPB bands?
Isoforms · Only one isoform is listed, with no alternative sequence supplied. Do not assign multiple bands to annotated isoforms on this evidence. Check whether the antibody recognizes different NPPB forms before interpreting extra bands.
Which NPPB glycosylation sites matter when interpreting bands?
PTM · UniProt annotates O-linked sites at Ser41, Thr62 (partial), Ser63, Ser70, Thr74, Ser79, Thr84 (partial), and Thr97. Ser41 carries a chondroitin sulfate annotation. Record these as UniProt coordinates when comparing antibody or paper numbering; the annotations alone cannot assign a particular band.
Does this guide establish induction of NPPB?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for NPPB Western blot?
Transfer · NPPB is a small, 14.7 kDa predicted precursor with a signal peptide at residues 1–26. Choose transfer conditions that retain small proteins, and verify retention with an appropriate molecular-weight marker. The supplied features do not establish one optimal transfer method.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the M01186-2 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should NPPB secretion affect sample choice and quantitation?
Quantitation · The supplied location annotation identifies NT-proBNP as secreted and detected in blood. State whether measurements come from cells or extracellular samples, and compare like sample types and preparation conditions. The features alone do not establish a conversion between band intensity and total NPPB production.
Why might NPPB migrate differently from its predicted 14.7 kDa?
Interpretation · The 14.7 kDa value is for the 134-residue sequence. NPPB has a signal peptide at residues 1–26 and eight annotated O-linked glycosylation sites. These features affect what molecular form an antibody detects, but they do not establish an apparent band size or prove a visible shift; no observed band is supplied.
One disulfide bond is annotated. Record whether samples were reduced when comparing blots, since reduction can change protein conformation. The annotation supplies neither bond coordinates nor an expected apparent mass, so it cannot identify a band by itself.
Compare bands with the 14.7 kDa precursor prediction while accounting for the signal peptide at residues 1–26 and eight annotated O-linked sites. The supplied features support several possible molecular forms but give no observed band size. Confirm antibody recognition and sample preparation before assigning an unexpected band to NPPB.
One disulfide bond is annotated. Record whether samples were reduced when comparing blots, since reduction can change protein conformation. The annotation supplies neither bond coordinates nor an expected apparent mass, so it cannot identify a band by itself.
Compare bands with the 14.7 kDa precursor prediction while accounting for the signal peptide at residues 1–26 and eight annotated O-linked sites. The supplied features support several possible molecular forms but give no observed band size. Confirm antibody recognition and sample preparation before assigning an unexpected band to NPPB.
Boster reagents
NPPB Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-BNP Rabbit Monoclonal Antibody
Cat # M01186-2
The catalog reports one anti-NPPB antibody for Western blot: M01186-2, a rabbit monoclonal labeled Anti-BNP. Its WB image shows BNP expression in human plasma lysate; the supplied evidence does not establish performance in other samples or species.
Which to pick: M01186-2 is the only listed option. It has stated human reactivity and a WB image using human plasma lysate. For other sample types or species, the supplied evidence does not show validation.
Source: BosterBio NPPB gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P16860.
- Human Protein Atlas. NPPB tissue expression.
- PMC12903334 — target-verified WB comparison
- PMC11339448 — target-verified WB comparison